Enfermedades Infecciosas y Microbiología

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Enfermedades Infecciosas y Microbiología >Year 2008, Issue 3

Castro AN, Carreón VED, Moreno GME, Alarcón RLC
Molecular characterization of extended spectrum β-lactamases-producing Escherichia coli
Enf Infec Microbiol 2008; 28 (3)

Language: Español
References: 24
Page: 114-120
PDF: 86.75 Kb.

Full text


Resistance to third generation cephalosporins is increasing. This resistance is explained by the acquisition and expression of extended spectrum β-lactamases (ESBL) enzymes among Gram-negative. Therefore, infections due to ESBL isolates continue to pose a challenge to infection management worldwide. The objective was to determine the existence of and describe phenotypic and genotypic characteristics of ESBL in Escherichia coli isolates. Thirty E. coli isolates where analyzed. The isolates were obtained from patients with nosocomial infection at two hospitals in the State of Guerrero, Mexico. They were collected during the period of November 2002 through October 2004. Antimicrobial susceptibility tests were performed and the β-lactamases were characterized by isoelectric focusing (IFE) and chain reaction of the polimerasa (PCR). Plasmid extraction and bacterial conjugations were performed as well. The results showed that 40% of these isolates were resistant to ceftriaxone, ceftazidime, and cefepime. The proportion of ESBL producers was 40%. The IEF demonstrated six β-lactamases with isoelectric points of 5.4, 7.0, 7.6, 7.8, 8.2 and 9.0. Specific PCR amplification confirmed that E. coli isolates harbored genes blaTEM, blaSHV, blaTLA and blaCTX. Fifteen of the isolates (50%) were able to transfer plasmids of 93 and 170 kb. This study shows the presence of ESBL genes among E. coli isolates in the two hospitals. There is a need to institute strict hospital infection control policies and regular surveillance of resistance to antimicrobial agents.

Key words: Escherichia coli, extended-spectrum β-lactamases, phenotypic characteristics, genotypic characteristics.


  1. Ronald A. “The etiology of urinary tract infection: traditional and emerging pathogens”. Am J Med 2002; 113:14S-19S

  2. Carratalà J, Mykietiuk A, Fernández-Sabé N, Suárez C, Dorca J, Verdaguer R, Manresa F, Gudiol F. “Health careassociated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes”. Arch Intern Med 2008; 168:109-10

  3. Paterson DL. “Resistance in Gram-negative bacteria: Enterobacteriaceae”. Am J Med 2006; 119: 520-528

  4. Dupont H. “The empiric treatment of nosocomial intraabdominal infections”. Int J Infect Dis. 2007; 11: S1-6

  5. Kang CI, Kim SH, Park W, Lee KD, Kim HB, Kim EC, et al. “Bloodstream Infections Due to Extended-Spectrum B-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Mortality and Treatment Outcome, with Special Emphasis on Antimicrobial Therapy”. Antimicrob Agents Chemother 2004; 48: 4574-4581

  6. Blomberg BR, Jureen K, Manji B, Tamim D, Mwakagile W, Urassa M, et al. “High rate of fatal cases of pediatric septicemia caused by Gram negative bacteria with extended spectrum B-lactamases in Dar Es Salaam, Tanzania”. J Clin Microbiol 2005; 43: 745-749.

  7. Livemore DM. "B-lactamases in laboratory and clinical resistance”. Clin Microbiol Rev 1995; 8: 557-584

  8. Bradford PA. “Extended-spectrum B-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat”. Clin Microbiol Rev 2001; 14: 933-9551

  9. Oteo J, Navarro C, Cercenado E, Delgado-Iribarren A, Wilhelmi I, OrdenB, et al. “Spread of Escherichia coli strain with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions”. J Clin Microbiol 2006; 44: 2359-2366

  10. Edelstein M, Pimkin M, Palagin I, Edelstein I y Stratchounski L. “Prevalence and Molecular Epidemiology of CTX-M Extended-Spectrum B-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in Russian Hospitals”. Antimicrob Agents Chemother 2003; 47: 3724-3732

  11. Quinteros M, Radice M, Rodríguez M, Costa N, Korbenfeld D, Couto E, et al.” Extended spectrum B-lactamases in Enterobacteriaceae in Buenos Aires, Argentina, Public Hospitals”. Antimicrob Agents Chemother 2003; 47: 2864-2867

  12. Essack SY, Hall LM, Pillay DG, Mcfadyen ML y Livermore DM. “Complexity and diversity of Klebsiella pneumonia strains with extended spectrum B-lactamases isolated in 1994 y 1996 at a teaching hospital in Durban, South Africa”. Antimicrob Agents Chemother 2001; 45: 88-95

  13. Miranda G, Castro N, Leaños B, Valenzuela A, Garza- Ramos U, Rojas T, et al. “Clonal and horizontal dissemination of Klebsiella pneumoniae expressing SHV-5 extended spectrum B-lactamase in a Mexican Pediatric Hospital”. J Clin Microbiol 2004; 42: 30-35

  14. Silva J, Aguilar C, Ayala G, Estrada MA, Garza-Ramos U, Lara-Lemus R, et al. “TLA-1: a new Plasmid-Mediated Extended-Espectrum B-Lactamase from Escherichia coli”. Antimicrob Agents Chemother 2000; 44: 997-1003

  15. Clinical Laboratory Standard Institute (CLSI/NCCLS). 2005c. Performance standars for antimicrobial susceptibility testing. Supplement M100-S15. CLSI, Wayne, PA

  16. Mattew M, Harris AM, Marshall MJ y Ross GW. “The use of analytical isoelectric focusing for detection and identification of B-lactamases”. J Gen Microbiol 1975; 88:169-78

  17. Silva J y Aguilar-Zacarias C. "B-lactamases Bioassay: A simplified method to determine extended-spectrum B-lactamases (ESBL) in enterobacterias”. Arch Med Res 1997;28: 285-287

  18. Kiesser T. “Factors affecting the isolation of DNA from Streptomyces lividans and Escherichia coli”. Plasmid 1984;12: 10-36

  19. Miller JH. Experiments in molecular genetics. Cold Spring Harbor Laboratory. USA: Cold Spring Harbor, 1992:82-85

  20. Arlet G y Philippon A. “Construction by polymerase chain reaction and use of intragenic DNA probes for three main types of transferiblle B-lactamases (TEM, SHV, CARB)“ FEMS Microbiol. Lett 1991; 82: 19-26

  21. Famiglietti A, Quinteros M, Vázquez M, Marín M, Ficola F, Radice M, et al. “Consenso sobre las pruebas de sensibilidad a los antimicrobianos en Enterobacteriaceae”. Rev Argen de Microbiol 2005; 37: 57-66

  22. Vignoli R, Varela G, Mota M, Cordeiro N, Power P, Ingold E, et al. “Enteropathogenic Escherichia coli strains carrying genes encoding the PER-2 and TEM-116 extended spectrum B-lactamases isolated from children with diarrhea in Uruguay”. J Clin Microbiol 2005; 43: 2940-2943

  23. Ndugulile F, Jureen R, Harthung S, Urassa W y Langeland N. “Extended Spectrum B-Lactamases among Gramnegative bacteria of nosocomial origin from an Intensive Care Unit of a tertiary health facility in Tanzania”. BMC Infect Dis 2005; 5: 86

  24. Pitout JD, Gregson D, Church D, Elsayed S y Laupland K. Community wide outbreaks of clonally related CTX-M-14 B-lactamase producing Escherichia coli strains in the Calgary Health region. J Clin Microbiol 2005; 43: 2844-2849

>Journals >Enfermedades Infecciosas y Microbiología >Year 2008, Issue 3

· Journal Index 
· Links 

Copyright 2019